New antibiotic oritavancin tested in kids for safety and dosing
NCT ID NCT02134301
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a single dose of the antibiotic oritavancin in 41 children under 18 with suspected or confirmed bacterial infections. The goal was to find the right dose and check for safety and side effects. It was an early-stage trial, so it focused on how the drug moves through the body and whether it is safe, not on curing the infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- oritavancin
- What this could lead to
- If successful, this could help determine the right dose of oritavancin for children with bacterial infections, potentially offering a new treatment option.
- What could go wrong
- This is an early Phase 1 trial with only 41 participants, focused on safety and dosing, not on proving effectiveness. The results may not lead to a widely approved treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAM-POSITIVE BACTERIAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arkansas Children's Hospital
Little Rock, Arkansas, 72202, United States
-
Children's Hospital of Orange County
Orange, California, 92868, United States
-
Rady Children's Hospital
San Diego, California, 92123, United States
-
Rainbow Babies and Children's Hospital
Cleveland, Ohio, 44106, United States
-
Toledo Children's Hospital
Toledo, Ohio, 43606, United States
-
UCLA Harbor Medical Center
Torrance, California, 90502, United States
-
Univ of Louisville, Norton Children's Research Institute
Louisville, Kentucky, 40202, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.